Results 11 to 20 of about 8,275 (209)

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update. [PDF]

Clin Pharmacol Ther
Thiopurine methyltransferase (TPMT) and Nudix hydrolase 15 (NUDT15) are key enzymes that catabolize thiopurines. Decreased or no‐function alleles in TPMT and NUDT15 are associated with reduced or no enzyme activity and predictive of pronounced adverse effects, including severe myelosuppression, that may occur among individuals treated with standard ...
Maillard M, Schwab M, Whirl-Carrillo M, Moyer AM, Suarez-Kurtz G, Pui CH, Stein CM, Klein TE, Spahn C, Kwon S, Hartono JL, de Boer NK, Ahmad T, Antillon-Klussmann FG, Caudle KE, Kato M, Yeoh AEJ, Schmiegelow K, Yang JJ.   +18 more
europepmc   +2 more sources

Clinical and Economic Impact of Expanded TPMT Testing to Prevent Thiopurine-Induced Myelosuppression in Australia: A Budget Impact Analysis. [PDF]

Clin Transl Sci
ABSTRACT Testing thiopurine methyltransferase (TPMT) enzyme activity or genotype prior to thiopurine prescribing is recommended to reduce the risk of moderate to severe—and potentially fatal—myelosuppression in poor or intermediate TPMT metabolizers. Despite this, only about one‐third of individuals prescribed thiopurines in Australia currently receive
Ianni BD, Ali MA, Yiu CH, Tan ECK, Lu CY.   +4 more
europepmc   +2 more sources

Genetic Determinants of Hematopoietic Toxicity Risk in Thai Pediatric Patients Undergoing 6-Mercaptopurine Treatment. [PDF]

Clin Transl Sci
ABSTRACT The nucleoside diphosphate‐linked moiety X‐type motif 15 (NUDT15) has been identified as a key genetic determinant of 6‐mercaptopurine (6‐MP)‐induced hematopoietic toxicity in populations with a high frequency of NUDT15 variants but a low frequency of thiopurine S‐methyltransferase (TPMT) variants.
Khaeso K, Chainansamit SO, Kuwatjanakul P, Komvilaisak P, Nakkam N, Suwannaying K, Vannaprasaht S, Dornsena A, Tassaneeyakul W.   +8 more
europepmc   +2 more sources

Unraveling Novel Genetic Determinants of Thiopurine Response Via TWAS. [PDF]

Clin Pharmacol Ther
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Thiopurines such as 6‐mercaptopurine (6MP) are essential in ALL maintenance therapy. However, dose‐limiting toxicities can significantly disrupt treatment. While genetic variants in TPMT and NUDT15 are known to affect thiopurine response, many patients with normal function ...
Bidoli C, Yang W, Karol SE, Lucafò M, Stocco G, Yang JJ.   +5 more
europepmc   +2 more sources

Economic evaluations of pharmacogenetic and pharmacogenomic screening tests : a systematic review : second update of the literature [PDF]

, 2016
Objective : Due to extended application of pharmacogenetic and pharmacogenomic screening (PGx) tests it is important to assess whether they provide good value for money. This review provides an update of the literature. Methods : A literature search was
Annemans, Lieven, Berm, Elizabeth JJ, Boersma, Cornelis, de Looff, Margot, Postma, Maarten J, van Boven, Job FM, Vegter, Stefan, Wilffert, Bob   +7 more
core   +9 more sources

Ancestry and TPMT-VNTR Polymorphism: Relationship with Hematological Toxicity in Uruguayan Patients with Acute Lymphoblastic Leukemia

Frontiers in Pharmacology, 2020
6-Mercaptopurine (6-MP) is a thiopurine drug widely used in childhood acute lymphoblastic leukemia (ALL) therapy. Genes such as TPMT and NUDT15 have an outstanding role in 6-MP metabolism.
Gabriela Burgueño-Rodríguez, Yessika Méndez, Natalia Olano, Agustín Dabezies, Bernardo Bertoni, Jorge Souto, Luis Castillo, Julio da Luz, Ana María Soler   +8 more
doaj   +1 more source

6-thioguanine treatment in inflammatory bowel disease: A critical appraisal by a European 6-TG working party [PDF]

, 2006
Recently, the suggestion to use 6-thioguanine (6-TG) as an alternative thiopurine in patients with inflammatory bowel disease (IBD) has been discarded due to reports about possible (hepato) toxicity. During meetings arranged in Vienna and Prague in 2004,
A. Teml, A.A. van Bodegraven, Al Hadithy AF, Artlich A, Bean RHD, Buffet C, C.J.J. Mulder, Carter MJ, Daniel F, De Boer N, de Boer NK, de Boer NK, de Jong D, Derijks LJ, Dervieux T, Dubinsky MC, Ferlitsch A, Fonseca V, Gane E, Gearry RB, H. Vogelsang, Haboubi NY, Herrlinger KR, Herrlinger KR, Herrlinger KR, J. Seiderer, Jones MC, K.R. Herrlinger, Katzka DA, Lilleyman JS, M. Lukas, M. Schwab, Marinaki AM, McBride KL, N.K.H. de Boer, Naber AH, P. Knoflach, Russmann S, Rutgeerts P, S. Almer, S.W. van der Merwe, Sandborn W, Schaeffeler E, Seiderer J, Shastri S, T. Ochsenkühn, Teml A, Teml A, Teml A, Tiede I, van Dieren JM, W. Petritsch, W. Reinisch   +52 more
core   +1 more source

Thiopurine -methyltransferase genetic polymorphisms in adult patients with inflammatory bowel diseases in the Latvian population

Therapeutic Advances in Gastroenterology, 2020
Background: Thiopurine methyltransferase (TPMT) plays a significant role in the metabolism of thiopurines, and, for patients with inflammatory bowel disease (IBD), it is useful to perform TPMT genotyping prior to azathioprine (AZA) treatment.
Polina Zalizko, Juris Stefanovics, Jelizaveta Sokolovska, Natalia Paramonova, Evija Klavina, Renars Erts, Vita Rovite, Janis Klovins, Aldis Pukitis   +8 more
doaj   +1 more source

Association between Thiopurine S-Methyltransferase Polymorphisms and Azathioprine-Induced Adverse Drug Reactions in Patients with Autoimmune Diseases: A Meta-Analysis. [PDF]

PLoS ONE, 2015
Azathioprine (AZA) is widely used as an immunosuppressive drug in autoimmune diseases, but its use is limited by significant adverse drug reactions (ADRs). Thiopurine S-methyltransferase (TPMT) is an important enzyme involved in AZA metabolism.
Yue-Ping Liu, Han-Qing Xu, Ming Li, Xiang Yang, Shu Yu, Wei-Ling Fu, Qing Huang   +6 more
doaj   +1 more source

Association between thiopurine S-methyltransferase polymorphisms and thiopurine-induced adverse drug reactions in patients with inflammatory bowel disease: a meta-analysis. [PDF]

PLoS ONE, 2015
Thiopurine drugs are well established treatments in the management of inflammatory bowel disease (IBD), but their use is limited by significant adverse drug reactions (ADRs).
Yue-Ping Liu, Hai-Yan Wu, Xiang Yang, Han-Qing Xu, Yong-Chuan Li, Da-Chuan Shi, Jun-Fu Huang, Qing Huang, Wei-Ling Fu   +8 more
doaj   +1 more source